Avelumab Injection

DRUG2 trials

Sponsors

iOnctura, Hospices Civils de Lyon

Conditions

Gestational Trophoblastic Neoplasias (GTN)MyelofibrosisNSCLCNon-Hodgkin Lymphoma, AdultSolid Tumor, AdultUveal Melanoma

Phase 1

A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers

Active, not recruitingNCT04328844

iOncturaMyelofibrosis, Non-Hodgkin Lymphoma, Adult, NSCLC +2

Start: 2020-02-25End: 2027-03-01Target: 210Updated: 2026-03-30

Avelumab and Methotrexate in in Low-risk Gestational Trophoblastic Neoplasias as First Line Treatment

RecruitingNCT04396223

Hospices Civils de LyonGestational Trophoblastic Neoplasias (GTN)

Start: 2020-02-12End: 2028-10-12Target: 26Updated: 2024-02-29

Related Papers

Roginolisib (IOA-244), an orally bioavailable, selective PI3Kδ inhibitor, in combination with venetoclax and rituximab in patients with relapsed chronic lymphocytic leukemia (CLL)

Blood2025-11-03

Trial in progress: A study of roginolisib in combination with ruxolitinib in patients with myelofibrosis who are unresponsive to JAK inhibitors (HEMA-MED)

Blood2025-11-03

Abstract 2055: Molecular profiling of the PI3Kδ inhibitor roginolisib in metastatic uveal melanoma and its correlation with clinical outcomes

Cancer Research2025-04-21

Roginolisib, an oral, highly selective and allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kδ) in patients with uveal melanoma and advanced cancers.

Journal of Clinical Oncology2024-06-013 citations

Roginolisib a Highly Selective Allosteric Modulator of the Phosphoinositide 3-Kinase Delta (PI3Kδ) in Patients with Refractory/Relapsed Follicular Lymphoma

Blood2023-11-021 citations

First-in-human (FIH) phase I dose escalation study (part A) of the first oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kδ) roginolisib in patients with advanced cancer and dose confirmation in uveal melanoma (part B).

Journal of Clinical Oncology2023-06-012 citations

Highly Selective Allosteric Modulator of the Phosphoinositide 3‐Kinase Delta (PI3Kδ) Roginolisib In Patients With Refractory/Relapsed Follicular Lymphoma

Hematological Oncology2023-06-012 citations

53P Characterization of the non-ATP competitive PI3Kdelta inhibitor IOA-244 in lymphoma models: From single agent to combination screen and clinical investigation

ESMO Open2023-03-01

First-in-human (FIH) phase I study of the highly selective phosphoinositide 3-kinase inhibitor delta (PI3Kδ) inhibitor IOA-244 in patients with advanced cancer: Safety, activity, pharmacokinetic (PK), and pharmacodynamic (PD) results.

Journal of Clinical Oncology2022-06-017 citations

Avelumab in Patients With Gestational Trophoblastic Tumors With Resistance to Single-Agent Chemotherapy: Cohort A of the TROPHIMMUN Phase II Trial

Journal of Clinical Oncology2020-07-2799 citations